During the initial time period of care, patients responding to antiretroviral therapy may develop an inflammatory manner to indolent or constituent opportunistic infections.
LEXIVA is contraindicated with fungus derivatives, cisapride, pimozide, midazolam and triazolam. If LEXIVA is coadministered with ritonavir, flecainide and propafenone are also contraindicated. Discernment should be used when coadministering medications that are substrates, inhibitors or inducers of CYP3A4, or potentially toxic medications that are metabolized by CYP3A4. Serious and/or life-threatening drug interactions could occur between LEXIVA and amiodarone, lidocaine (systemic), tricyclic antidepressants and quinidine. Density monitoring of these agents is recommended if these agents are used concomitantly with LEXIVA. LEXIVA should not be coadministered with rifampin, St. John'swort, lovastatin, simvastatin or delavirdine. Component part forethought should be used when prescribing phosphodiesterase (PDE-5) inhibitors for erectile dysfunction (e.g., sildenafil or vardenafil) in patients receiving LEXIVA. This list of potency drug interactions is not complete.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment